

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

Department of the Treasury Internal Revenue Service

The organization may have to use a copy of this return to satisfy state reporting requirements.

A For the 2003 calendar year, or tax year beginning SEP 1, 2003 and ending AUG 31, 2004

B Check if applicable: C Name of organization: ASCO FOUNDATION D Employer identification number: 31-1667995 E Telephone number: (703) 299-0150

G Website: N/A J Organization type: 501(c)(3) K Check here: if the organization's gross receipts are normally not more than \$25,000. H and I are not applicable to section 527 organizations.

L Gross receipts: Add lines 6b, 8b, 9b, and 10b to line 12: 18,711,480. M Check: if the organization is not required to attach Sch. B (Form 990, 990-EZ, or 990-PF)

Part I Revenue, Expenses, and Changes in Net Assets or Fund Balances

Table with 21 rows and 4 columns. Rows include: 1 Contributions, gifts, grants, and similar amounts received; 2 Program service revenue; 3 Membership dues and assessments; 4 Interest on savings and temporary cash investments; 5 Dividends and interest from securities; 6a Gross rents; 6b Less rental expenses; 6c Net rental income; 7 Other investment income; 8a Gross amount from sales of assets other than inventory; 8b Less cost or other basis and sales expenses; 8c Gain or (loss); 8d Net gain or (loss); 9 Special events and activities; 9a Gross revenue; 9b Less direct expenses; 9c Net income; 10a Gross sales of inventory; 10b Less cost of goods sold; 10c Gross profit; 11 Other revenue; 12 Total revenue; 13 Total expenses; 14 Management and general; 15 Fundraising; 16 Payments to affiliates; 17 Total expenses; 18 Excess (deficit) for the year; 19 Net assets or fund balances at beginning of year; 20 Other changes in net assets or fund balances; 21 Net assets or fund balances at end of year.

SCANNED MAY 11 2005

Part I Statement of Functional Expenses

All organizations must complete column (A). Columns (B), (C), and (D) are required for section 501(c)(3) and (4) organizations and section 4947(a)(1) nonexempt charitable trusts but optional for others.

Do not include amounts reported on line 6b, 8b, 9b, 10b, or 16 of Part I.	(A) Total	(B) Program services	(C) Management and general	(D) Fundraising
22 Grants and allocations (attach schedule) cash \$16978246 noncash \$	22 16,978,246.	16,978,246.	STATEMENT 4	
23 Specific assistance to individuals (attach schedule)	23			
24 Benefits paid to or for members (attach schedule)	24			
25 Compensation of officers, directors, etc.	25 165,333.	0.	165,333.	0.
26 Other salaries and wages	26			
27 Pension plan contributions	27			
28 Other employee benefits	28			
29 Payroll taxes	29			
30 Professional fundraising fees	30 259,201.			259,201.
31 Accounting fees	31 1,800.		1,800.	
32 Legal fees	32 1,881.		1,636.	245.
33 Supplies	33 11,487.		6,561.	4,926.
34 Telephone	34 3,944.		3,478.	466.
35 Postage and shipping	35 44,049.		10,663.	33,386.
36 Occupancy	36 117,820.		117,820.	
37 Equipment rental and maintenance	37 819.		819.	
38 Printing and publications	38 99,116.		36,528.	62,588.
39 Travel	39 74,563.		20,034.	54,529.
40 Conferences, conventions, and meetings	40 48,906.		48,156.	750.
41 Interest	41			
42 Depreciation, depletion, etc. (attach schedule)	42			
43 Other expenses not covered above (itemize):				
a	43a			
b	43b			
c	43c			
d	43d			
e SEE STATEMENT 3	43e 681,700.	10,253.	631,651.	39,796.
44 Total functional expenses (total lines 22 through 43). Organizations completing columns (B)-(D), carry these totals to lines 13-15	44 18,488,865.	16,988,499.	1,044,479.	455,887.

Joint Costs. Check if you are following SOP 98-2

Are any joint costs from a combined educational campaign and fundraising solicitation reported in (B) Program services? Yes No

If "Yes," enter (i) the aggregate amount of these joint costs \$ _____, (ii) the amount allocated to Program services \$ _____,

(iii) the amount allocated to Management and general \$ _____, and (iv) the amount allocated to Fundraising \$ _____

Part II Statement of Program Service Accomplishments

What is the organization's primary exempt purpose?

SEE STATEMENT 10

All organizations must describe their exempt purpose achievements in a clear and concise manner. State the number of clients served, publications issued, etc. Discuss achievements that are not measurable. (Section 501(c)(3) and (4) organizations and 4947(a)(1) nonexempt charitable trusts must also enter the amount of grants and allocations to others.)

Program Service Expenses
(Required for 501(c)(3) and (4) orgs. and 4947(a)(1) trusts, but optional for others.)

a SEE STATEMENT 11				
	(Grants and allocations \$	16,978,246.)		16,988,499.
b				
	(Grants and allocations \$)		
c				
	(Grants and allocations \$)		
d				
	(Grants and allocations \$)		
e Other program services (attach schedule)				
	(Grants and allocations \$)		
f Total of Program Service Expenses (should equal line 44, column (B), Program services)				16,988,499.

Part I Balance Sheets

Note: Where required, attached schedules and amounts within the description column should be for end-of-year amounts only.

		(A) Beginning of year	(B) End of year
Assets	45 Cash - non-interest-bearing	107,971.	45 <38,984.>
	46 Savings and temporary cash investments	586,422.	46 3,654,080.
	47 a Accounts receivable	47a 25,950.	
	b Less: allowance for doubtful accounts	47b	47c 25,950.
	48 a Pledges receivable	48a 4,682,267.	
	b Less: allowance for doubtful accounts	48b	48c 4,682,267.
	49 Grants receivable		49
	50 Receivables from officers, directors, trustees, and key employees		50
	51 a Other notes and loans receivable	51a	
	b Less: allowance for doubtful accounts	51b	51c
	52 Inventories for sale or use		52
	53 Prepaid expenses and deferred charges	17,375.	53 18,270.
	54 Investments - securities	<input type="checkbox"/> Cost <input type="checkbox"/> FMV	54
	55 a Investments - land, buildings, and equipment basis	55a	
	b Less: accumulated depreciation	55b	55c
56 Investments - other		56	
57 a Land, buildings, and equipment: basis	57a		
b Less: accumulated depreciation	57b	57c	
58 Other assets (describe ▶ DUE FROM AFFILIATE)		58 196,660.	
59 Total assets (add lines 45 through 58) (must equal line 74)	3,656,618.	59 8,538,243.	
Liabilities	60 Accounts payable and accrued expenses	2,300.	60 4,018,835.
	61 Grants payable		61
	62 Deferred revenue	380,000.	62 725,000.
	63 Loans from officers, directors, trustees, and key employees		63
	64 a Tax-exempt bond liabilities		64a
	b Mortgages and other notes payable		64b
	65 Other liabilities (describe ▶ PAYABLE TO AFFILIATE)	104,519.	65 159,555.
66 Total liabilities (add lines 60 through 65)	486,819.	66 4,903,390.	
Net Assets or Fund Balances	Organizations that follow SFAS 117, check here <input checked="" type="checkbox"/> and complete lines 67 through 69 and lines 73 and 74.		
	67 Unrestricted	3,169,799.	67 2,950,784.
	68 Temporarily restricted		68 684,069.
	69 Permanently restricted		69
	Organizations that do not follow SFAS 117, check here <input type="checkbox"/> and complete lines 70 through 74		
	70 Capital stock, trust principal, or current funds		70
	71 Paid-in or capital surplus, or land, building, and equipment fund		71
	72 Retained earnings, endowment, accumulated income, or other funds		72
73 Total net assets or fund balances (add lines 67 through 69 or lines 70 through 72, column (A) must equal line 19, column (B) must equal line 21)	3,169,799.	73 3,634,853.	
74 Total liabilities and net assets / fund balances (add lines 66 and 73)	3,656,618.	74 8,538,243.	

Form 990 is available for public inspection and, for some people, serves as the primary or sole source of information about a particular organization. How the public perceives an organization in such cases may be determined by the information presented on its return. Therefore, please make sure the return is complete and accurate and fully describes, in Part III, the organization's programs and accomplishments

Other information

		Yes	No
76	Did the organization engage in any activity not previously reported to the IRS? If "Yes," attach a detailed description of each activity		X
77	Were any changes made in the organizing or governing documents but not reported to the IRS? If "Yes," attach a conformed copy of the changes.		X
78a	Did the organization have unrelated business gross income of \$1,000 or more during the year covered by this return?		X
78b	If "Yes," has it filed a tax return on Form 990-T for this year? N/A		
79	Was there a liquidation, dissolution, termination, or substantial contraction during the year? If "Yes," attach a statement		X
80a	Is the organization related (other than by association with a statewide or nationwide organization) through common membership, governing bodies, trustees, officers, etc., to any other exempt or nonexempt organization?	X	
80b	If "Yes," enter the name of the organization AMERICAN SOCIETY OF CLINICAL ONCOLOGY and check whether it is <input checked="" type="checkbox"/> exempt or <input type="checkbox"/> nonexempt.		
81a	Enter direct or indirect political expenditures See line 81 instructions 81a 0		
81b	Did the organization file Form 1120-POL for this year?		X
82a	Did the organization receive donated services or the use of materials, equipment, or facilities at no charge or at substantially less than fair rental value?		X
82b	If "Yes," you may indicate the value of these items here. Do not include this amount as revenue in Part I or as an expense in Part II. (See instructions in Part III.) 82b N/A		
83a	Did the organization comply with the public inspection requirements for returns and exemption applications?	X	
83b	Did the organization comply with the disclosure requirements relating to quid pro quo contributions?	X	
84a	Did the organization solicit any contributions or gifts that were not tax deductible?		X
84b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible? N/A		
85a	501(c)(4), (5), or (6) organizations. a Were substantially all dues nondeductible by members? N/A		
85b	Did the organization make only in-house lobbying expenditures of \$2,000 or less? N/A		
85c	Dues, assessments, and similar amounts from members 85c N/A		
85d	Section 162(e) lobbying and political expenditures 85d N/A		
85e	Aggregate nondeductible amount of section 6033(e)(1)(A) dues notices 85e N/A		
85f	Taxable amount of lobbying and political expenditures (line 85d less 85e) 85f N/A		
85g	Does the organization elect to pay the section 6033(e) tax on the amount on line 85f? N/A		
85h	If section 6033(e)(1)(A) dues notices were sent, does the organization agree to add the amount on line 85f to its reasonable estimate of dues allocable to nondeductible lobbying and political expenditures for the following tax year? N/A		
86a	501(c)(7) organizations. Enter: a Initiation fees and capital contributions included on line 12 86a N/A		
86b	Gross receipts, included on line 12, for public use of club facilities 86b N/A		
87a	501(c)(12) organizations. Enter: a Gross income from members or shareholders 87a N/A		
87b	Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.) 87b N/A		
88	At any time during the year, did the organization own a 50% or greater interest in a taxable corporation or partnership, or an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Part IX		X
89a	501(c)(3) organizations. Enter. Amount of tax imposed on the organization during the year under: section 4911 0.; section 4912 0.; section 4955 0.		
89b	501(c)(3) and 501(c)(4) organizations. Did the organization engage in any section 4958 excess benefit transaction during the year or did it become aware of an excess benefit transaction from a prior year? If "Yes," attach a statement explaining each transaction		X
	c Enter: Amount of tax imposed on the organization managers or disqualified persons during the year under sections 4912, 4955, and 4958		0.
	d Enter: Amount of tax on line 89c, above, reimbursed by the organization		0.
90a	List the states with which a copy of this return is filed VIRGINIA		
90b	Number of employees employed in the pay period that includes March 12, 2003		0
91	The books are in care of MANAGEMENT Telephone no. (703) 299-0150		
	Located at 1900 DUKE STREET, SUITE 200, ALEXANDRIA, VA ZIP +4 22314		
92	Section 4947(a)(1) nonexempt charitable trusts filing Form 990 in lieu of Form 1041- Check here and enter the amount of tax-exempt interest received or accrued during the tax year		N/A

Part VII Analysis of Income-Producing Activities (See page 33 of the instructions.)

Note: Enter gross amounts unless otherwise indicated.

	Unrelated business income		Excluded by section 512, 513, or 514		(E) Related or exempt function income
	(A) Business code	(B) Amount	(C) Exclu- sion code	(D) Amount	
93 Program service revenue:					
a _____					
b _____					
c _____					
d _____					
e _____					
f Medicare/Medicaid payments					
g Fees and contracts from government agencies					
94 Membership dues and assessments					
95 Interest on savings and temporary cash investments			14	27,573.	
96 Dividends and interest from securities					
97 Net rental income or (loss) from real estate:					
a debt-financed property					
b not debt-financed property					
98 Net rental income or (loss) from personal property					
99 Other investment income					
100 Gain or (loss) from sales of assets other than inventory					
101 Net income or (loss) from special events			01	<581,480.>	
102 Gross profit or (loss) from sales of inventory					
103 Other revenue:					
a OTHER REVENUE					101,482.
b _____					
c _____					
d _____					
e _____					
104 Subtotal (add columns (B), (D), and (E))		0.		<553,907.>	101,482.
105 Total (add line 104, columns (B), (D), and (E))					<452,425.>

Note: Line 105 plus line 1d, Part I, should equal the amount on line 12, Part I.

Part VIII Relationship of Activities to the Accomplishment of Exempt Purposes (See page 34 of the instructions.)

Line No. Explain how each activity for which income is reported in column (E) of Part VII contributed importantly to the accomplishment of the organization's exempt purposes (other than by providing funds for such purposes).

103A RETURNED GRANT AWARDS.

Part IX Information Regarding Taxable Subsidiaries and Disregarded Entities (See page 34 of the instructions.)

(A) Name, address, and EIN of corporation, partnership, or disregarded entity	(B) Percentage of ownership interest	(C) Nature of activities	(D) Total income	(E) End-of-year assets
N/A	%			
	%			
	%			
	%			

Part X Information Regarding Transfers Associated

- (a) Did the organization, during the year, receive any funds, directly or indirectly, from any individual?
- (b) Did the organization, during the year, pay premiums, directly or indirectly, on behalf of any individual?

Note: If "Yes" to (b), file Form 8870 and Form 4720 (see instructions).

Please Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature of officer: *[Signature]* Date: 4/1

Paid Preparer's Use Only

Preparer's signature: *[Signature]*

Firm's name (or yours if self-employed), address, and ZIP + 4: DELOITTE TAX LLP, 1750 TYSONS BLVD, MCLEAN, VA 22102-4219

323161 12-17-03

SCHEDULE A
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Organization Exempt Under Section 501(c)(3)

(Except Private Foundation) and Section 501(e), 501(f), 501(k),
501(n), or Section 4947(a)(1) Nonexempt Charitable Trust

Supplementary Information-(See separate instructions.)

▶ **MUST be completed by the above organizations and attached to their Form 990 or 990-EZ**

OMB No 1545-0047

2003

Name of the organization **ASCO FOUNDATION** Employer identification number **31: 1667995**

Part I Compensation of the Five Highest Paid Employees Other Than Officers, Directors, and Trustees
(See page 1 of the instructions List each one If there are none, enter "None ")

(a) Name and address of each employee paid more than \$50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans & deferred compensation	(e) Expense account and other allowances
NONE				
Total number of other employees paid over \$50,000	0			

Part II Compensation of the Five Highest Paid Independent Contractors for Professional Services
(See page 2 of the instructions. List each one (whether individuals or firms) If there are none, enter "None.")

(a) Name and address of each independent contractor paid more than \$50,000	(b) Type of service	(c) Compensation
ONLINE PRODUCTIONS 651 W MT. PLEASANT AVE. STE 225, LIVINGSTON, NJ	PRODUCTION COMPANY	301,904.
DEE CHAMBERLIN 15145 PAWNEE CIRCLE, LEAWOOD, KS 66224	CONSULTING FIRM	220,425.
NEVILLE PRODUCTIONS 360 17TH ST. #200 OAKLAND, CA 94612	ENTERTAINMENT COMPANY	125,000.
WILLIAM MORRIS AGENCY, INC. 151 EL CAMINO DR. BEVERLY HILLS, CA 90212	TALENT AGENCY	125,000.
BELIN ASSOCIATES 1554 S. SEPULVEDA BLVD. #209 LOS ANGELES, CA	CONSULTING FIRM	97,180.
Total number of others receiving over \$50,000 for professional services	0	

Part III **Statements About Activities** (See page 2 of the instructions)

		Yes	No
1	During the year, has the organization attempted to influence national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum? If "Yes," enter the total expenses paid or incurred in connection with the lobbying activities ▶ \$ _____ \$ _____ (Must equal amounts on line 38, Part VI-A, or line i of Part VI-B) Organizations that made an election under section 501(h) by filing Form 5768 must complete Part VI-A. Other organizations checking "Yes," must complete Part VI-B AND attach a statement giving a detailed description of the lobbying activities.		X
2	During the year, has the organization, either directly or indirectly, engaged in any of the following acts with any substantial contributors, trustees, directors, officers, creators, key employees, or members of their families, or with any taxable organization with which any such person is affiliated as an officer, director, trustee, majority owner, or principal beneficiary? (If the answer to any question is "Yes," attach a detailed statement explaining the transactions.)		
a	Sale, exchange, or leasing of property?		X
b	Lending of money or other extension of credit?		X
c	Furnishing of goods, services, or facilities?		X
d	Payment of compensation (or payment or reimbursement of expenses if more than \$1,000)?		X
e	Transfer of any part of its income or assets?		X
3 a	Do you make grants for scholarships, fellowships, student loans, etc ? (If "Yes," attach an explanation of how you determine that recipients qualify to receive payments.)	X	
b	Do you have a section 403(b) annuity plan for your employees?		X
4	Did you maintain any separate account for participating donors where donors have the right to provide advice on the use or distribution of funds?		X

SEE STATEMENT 9

Part IV **Reason for Non-Private Foundation Status** (See pages 3 through 6 of the instructions.)

- The organization is not a private foundation because it is: (Please check only **ONE** applicable box.)
- 5 A church, convention of churches, or association of churches. Section 170(b)(1)(A)(i)
 - 6 A school. Section 170(b)(1)(A)(ii). (Also complete Part V.)
 - 7 A hospital or a cooperative hospital service organization. Section 170(b)(1)(A)(iii).
 - 8 A Federal, state, or local government or governmental unit. Section 170(b)(1)(A)(v).
 - 9 A medical research organization operated in conjunction with a hospital. Section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state **▶** _____
 - 10 An organization operated for the benefit of a college or university owned or operated by a governmental unit. Section 170(b)(1)(A)(iv). (Also complete the **Support Schedule** in Part IV-A.)
 - 11a An organization that normally receives a substantial part of its support from a governmental unit or from the general public. Section 170(b)(1)(A)(vi). (Also complete the **Support Schedule** in Part IV-A.)
 - 11b A community trust. Section 170(b)(1)(A)(vi). (Also complete the **Support Schedule** in Part IV-A.)
 - 12 An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its charitable, etc., functions - subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Also complete the **Support Schedule** in Part IV-A.)
 - 13 An organization that is not controlled by any disqualified persons (other than foundation managers) and supports organizations described in (1) lines 5 through 12 above; or (2) section 501(c)(4), (5), or (6), if they meet the test of section 509(a)(2). (See section 509(a)(3).)

Provide the following information about the supported organizations (See page 5 of the instructions.)

(a) Name(s) of supported organization(s)	(b) Line number from above
	12

- 14 An organization organized and operated to test for public safety. Section 509(a)(4). (See page 6 of the instructions.)

Part IV-A Support Schedule (Complete only if you checked a box on line 10, 11, or 12.) Use cash method of accounting. **N/A**
 Note: You may use the worksheet in the instructions for converting from the accrual to the cash method of accounting.

Calendar year (or fiscal year beginning in)	(a) 2002	(b) 2001	(c) 2000	(d) 1999	(e) Total
15 Gifts, grants, and contributions received (Do not include unusual grants. See line 28.)					
16 Membership fees received					
17 Gross receipts from admissions, merchandise sold or services performed, or furnishing of facilities in any activity that is related to the organization's charitable, etc., purpose					
18 Gross income from interest, dividends, amounts received from payments on securities loans (section 512(a)(5)), rents, royalties, and unrelated business taxable income (less section 511 taxes) from businesses acquired by the organization after June 30, 1975					
19 Net income from unrelated business activities not included in line 18					
20 Tax revenues levied for the organization's benefit and either paid to it or expended on its behalf					
21 The value of services or facilities furnished to the organization by a governmental unit without charge. Do not include the value of services or facilities generally furnished to the public without charge.					
22 Other income. Attach a schedule. Do not include gain or (loss) from sale of capital assets.					
23 Total of lines 15 through 22	0.	0.	0.	0.	0.
24 Line 23 minus line 17					
25 Enter 1% of line 23					

26 Organizations described on lines 10 or 11: a Enter 2% of amount in column (e), line 24.	26a	N/A
b Prepare a list for your records to show the name of and amount contributed by each person (other than a governmental unit or publicly supported organization) whose total gifts for 1999 through 2002 exceeded the amount shown in line 26a. Do not file this list with your return. Enter the total of all these excess amounts.	26b	N/A
c Total support for section 509(a)(1) test. Enter line 24, column (e).	26c	N/A
d Add: Amounts from column (e) for lines: 18 _____ 19 _____ 22 _____ 26b _____	26d	N/A
e Public support (line 26c minus line 26d total)	26e	N/A
f Public support percentage (line 26e (numerator) divided by line 26c (denominator))	26f	N/A %

27 Organizations described on line 12: a For amounts included in lines 15, 16, and 17 that were received from a "disqualified person," prepare a list for your records to show the name of, and total amounts received in each year from, each "disqualified person." Do not file this list with your return. Enter the sum of such amounts for each year.	(2002)	(2001)	(2000)	(1999)
b For any amount included in line 17 that was received from each person (other than "disqualified persons"), prepare a list for your records to show the name of, and amount received for each year, that was more than the larger of (1) the amount on line 25 for the year or (2) \$5,000. (Include in the list organizations described in lines 5 through 11, as well as individuals.) Do not file this list with your return. After computing the difference between the amount received and the larger amount described in (1) or (2), enter the sum of these differences (the excess amounts) for each year.	(2002)	(2001)	(2000)	(1999)
c Add: Amounts from column (e) for lines: 15 _____ 16 _____ 17 _____ 20 _____ 21 _____	27c	N/A		
d Add: Line 27a total _____ and line 27b total _____	27d	N/A		
e Public support (line 27c total minus line 27d total)	27e	N/A		
f Total support for section 509(a)(2) test. Enter amount on line 23, column (e).	27f	N/A		
g Public support percentage (line 27e (numerator) divided by line 27f (denominator))	27g	N/A %		
h Investment income percentage (line 18, column (e) (numerator) divided by line 27f (denominator))	27h	N/A %		

28 **Unusual Grants:** For an organization described in line 10, 11, or 12 that received any unusual grants during 1999 through 2002, prepare a list for your records to show, for each year, the name of the contributor, the date and amount of the grant, and a brief description of the nature of the grant. Do not file this list with your return. Do not include these grants in line 15.

Part V Private School Questionnaire (See page 7 of the instructions.)

N/A

(To be completed ONLY by schools that checked the box on line 6 in Part IV)

		Yes	No
29	Does the organization have a racially nondiscriminatory policy toward students by statement in its charter, bylaws, other governing instrument, or in a resolution of its governing body?		
30	Does the organization include a statement of its racially nondiscriminatory policy toward students in all its brochures, catalogues, and other written communications with the public dealing with student admissions, programs, and scholarships?		
31	Has the organization publicized its racially nondiscriminatory policy through newspaper or broadcast media during the period of solicitation for students, or during the registration period if it has no solicitation program, in a way that makes the policy known to all parts of the general community it serves? If "Yes," please describe; if "No," please explain. (If you need more space, attach a separate statement.)		
<hr/> <hr/> <hr/>			
32	Does the organization maintain the following.		
a	Records indicating the racial composition of the student body, faculty, and administrative staff?	32a	
b	Records documenting that scholarships and other financial assistance are awarded on a racially nondiscriminatory basis?	32b	
c	Copies of all catalogues, brochures, announcements, and other written communications to the public dealing with student admissions, programs, and scholarships?	32c	
d	Copies of all material used by the organization or on its behalf to solicit contributions? If you answered "No" to any of the above, please explain. (If you need more space, attach a separate statement)	32d	
<hr/> <hr/> <hr/>			
33	Does the organization discriminate by race in any way with respect to.		
a	Students' rights or privileges?	33a	
b	Admissions policies?	33b	
c	Employment of faculty or administrative staff?	33c	
d	Scholarships or other financial assistance?	33d	
e	Educational policies?	33e	
f	Use of facilities?	33f	
g	Athletic programs?	33g	
h	Other extracurricular activities? If you answered "Yes" to any of the above, please explain. (If you need more space, attach a separate statement)	33h	
<hr/> <hr/> <hr/>			
34 a	Does the organization receive any financial aid or assistance from a governmental agency?	34a	
b	Has the organization's right to such aid ever been revoked or suspended? If you answered "Yes" to either 34a or b, please explain using an attached statement.	34b	
35	Does the organization certify that it has complied with the applicable requirements of sections 4 01 through 4.05 of Rev. Proc. 75-50, 1975-2 C.B. 587, covering racial nondiscrimination? If "No," attach an explanation	35	

Part VI-A Lobbying Expenditures by Electing Public Charities (See page 9 of the instructions)

N/A

(To be completed ONLY by an eligible organization that filed Form 5768)

Check **a** if the organization belongs to an affiliated group Check **b** if you checked "a" and "limited control" provisions apply.

Limits on Lobbying Expenditures

(The term "expenditures" means amounts paid or incurred)

	(a) Affiliated group totals	(b) To be completed for ALL electing organizations
	N/A	
36 Total lobbying expenditures to influence public opinion (grassroots lobbying)	36	
37 Total lobbying expenditures to influence a legislative body (direct lobbying)	37	
38 Total lobbying expenditures (add lines 36 and 37)	38	
39 Other exempt purpose expenditures	39	
40 Total exempt purpose expenditures (add lines 38 and 39)	40	
41 Lobbying nontaxable amount Enter the amount from the following table -		
If the amount on line 40 is -		
The lobbying nontaxable amount is -		
Not over \$500,000	20% of the amount on line 40	}
Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000	
Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000	
Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000	
Over \$17,000,000	\$1,000,000	
42 Grassroots nontaxable amount (enter 25% of line 41)	42	
43 Subtract line 42 from line 36. Enter -0- if line 42 is more than line 36	43	
44 Subtract line 41 from line 38. Enter -0- if line 41 is more than line 38	44	

Caution: If there is an amount on either line 43 or line 44, you must file Form 4720.

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 45 through 50 on page 11 of the instructions.)

Calendar year (or fiscal year beginning in)	Lobbying Expenditures During 4-Year Averaging Period				N/A
	(a) 2003	(b) 2002	(c) 2001	(d) 2000	(e) Total
45 Lobbying nontaxable amount					0.
46 Lobbying ceiling amount (150% of line 45(e))					0.
47 Total lobbying expenditures					0.
48 Grassroots nontaxable amount					0.
49 Grassroots ceiling amount (150% of line 48(e))					0.
50 Grassroots lobbying expenditures					0.

Part VI-B Lobbying Activity by Nonelecting Public Charities

(For reporting only by organizations that did not complete Part VI-A) (See page 12 of the instructions)

N/A

During the year, did the organization attempt to influence national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

	Yes	No	Amount
a Volunteers			
b Paid staff or management (Include compensation in expenses reported on lines c through h.)			
c Media advertisements			
d Mailings to members, legislators, or the public			
e Publications, or published or broadcast statements			
f Grants to other organizations for lobbying purposes			
g Direct contact with legislators, their staffs, government officials, or a legislative body			
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any other means			
i Total lobbying expenditures (Add lines c through h.)			0.

If "Yes" to any of the above, also attach a statement giving a detailed description of the lobbying activities.

THE ASCO FOUNDATION
FOR THE YEAR ENDED
AUGUST 31, 2004

COMPANY	Net
Aventis Pharmaceuticals	150,000
The Breast Cancer Research Foundation	75,000
The Breast Cancer Research Foundation	75,000
The Breast Cancer Research Foundation	75,000
The Breast Cancer Research Foundation	75,000
The Breast Cancer Research Foundation	75,000
The Breast Cancer Research Foundation	75,000
Coalition of National Cancer Cooperative Groups	25,500
Aventis Pharmaceuticals	250,000
Abbott Laboratories	25,000
Allos Therapeutics	25,000
Amgen	75,000
Amgen	75,000
Antigenics	25,000
Antigenics	25,000
AstraZeneca Pharmaceuticals	100,000
Aventis Pharmaceuticals	-
Aventis Pharmaceuticals	75,000
Bayer Corporation	100,000
Berlex Laboratories	25,000
Berlex Laboratories	25,000
Bristol-Myers Squibb	25,000
GlaxoSmithKline	37,500
Merck & Co , Inc	25,000
MGI Pharma	75,000
MGI Pharma	50,000
MGI Pharma	50,000
Roche Pharmaceuticals	250,000
Sanofi-Synthelabo	75,000
Sanofi-Synthelabo	250,000
Sanofi-Synthelabo	150,000
Bristol-Myers Squibb	150,000
Aventis Pharmaceuticals	250,000
Genentech	125,000
Eli Lilly and Company	750,000
Eli Lilly and Company	-
Aventis Pharmaceuticals	100,000
Bristol-Myers Squibb	100,000
GlaxoSmithKline	25,000
Roche Pharmaceuticals	150,000
Roche Pharmaceuticals	150,000
Sanofi-Synthelabo	250,000
GlaxoSmithKline	-
Amgen	100,000
Amgen	75,000
Aventis Pharmaceuticals	100,000
Bristol-Myers Squibb	80,000
Bristol-Myers Squibb	50,000
Eli Lilly and Company	75,000
Genentech	100,000
Genentech	75,000
GlaxoSmithKline	37,500
GlaxoSmithKline	-
Millennium Pharmaceuticals	37,500
Ortho Biotech	50,000
Pfizer	50,000
Pfizer	-
Sanofi-Synthelabo	75,000
Amgen	25,000
Aventis Pharmaceuticals	25,000
Bristol-Myers Squibb	25,000
Eli Lilly and Company	25,000
Genentech	50,000
GlaxoSmithKline	25,000
Novartis Pharmaceuticals	25,000
Ortho Biotech	25,000
Sanofi-Synthelabo	50,000
AstraZeneca Pharmaceuticals	59,400
AstraZeneca Pharmaceuticals	59,400
AstraZeneca Pharmaceuticals	59,400
Genentech	59,400
Genentech	59,400
Genentech	59,400
Bristol-Myers Squibb	59,400
Bristol-Myers Squibb	59,400
Bristol-Myers Squibb	59,400
Aventis Pharmaceuticals	118,800

THE ASCO FOUNDATION
FOR THE YEAR ENDED
AUGUST 31, 2004

COMPANY	Net
Aventis Pharmaceuticals	118,800
Aventis Pharmaceuticals	118,800
Amgen	59,400
Amgen	59,400
Amgen	59,400
The Cancer Research Foundation of America	-
The Cancer Research Foundation of America	-
The Cancer Research Foundation of America	-
Sanofi-Synthelabo	59,400
Sanofi-Synthelabo	59,400
Sanofi-Synthelabo	59,400
Sanofi-Synthelabo	-
Sanofi-Synthelabo	-
Sanofi-Synthelabo	-
Eli Lilly and Company	118,800
Eli Lilly and Company	118,800
Eli Lilly and Company	118,800
The American Society of Clinical Oncology	59,400
The American Society of Clinical Oncology	59,400
The American Society of Clinical Oncology	59,400
Eli Lilly and Company	59,400
Eli Lilly and Company	59,400
Eli Lilly and Company	59,400
The Breast Cancer Research Foundation	170,100
Pancreatic Cancer Action Network	59,400
Pancreatic Cancer Action Network	59,400
Pancreatic Cancer Action Network	59,400
The American Society of Clinical Oncology	178,200
Amgen	25,000
Bayer Corporation	60,000
Aventis Pharmaceuticals	-
Sanofi-Synthelabo	250,000
Amgen	150,000
Abbott Laboratories	20,000
Oryx Pharmaceuticals	20,000
Sanofi-Synthelabo	16,500
Sanofi-Synthelabo	16,500
Amgen	150,000
Aventis Pharmaceuticals	50,000
Bristol-Myers Squibb	100,000
Eli Lilly and Company	100,000
Genentech	150,000
Novartis Pharmaceuticals	150,000
Pfizer	100,000
Roche Pharmaceuticals	150,000
Roche Pharmaceuticals	100,000
Sanofi-Synthelabo	150,000
Sanofi-Synthelabo	-
Sanofi-Synthelabo	50,000
Sanofi-Synthelabo	-
Sanofi-Synthelabo	75,000
Amgen	-
Genentech	100,000
Genentech	25,000
Academy for Healthcare Education	125,000
Academy for Healthcare Education	125,000
AstraZeneca Pharmaceuticals	50,000
Genentech	50,000
Genta	50,000
Health Science Communications	50,000
Ortho Biotech	125,000
Pharmion Corporation	75,000
Sanofi-Synthelabo	125,000
Bristol-Myers Squibb	100,000
Bristol-Myers Squibb	50,000
Aventis Pharmaceuticals	100,000
Bristol-Myers Squibb	100,000
Eli Lilly and Company	100,000
Genentech	75,000
NeoPharm	27,500
Novartis Pharmaceuticals	100,000
Aventis Pharmaceuticals	250,000
Aventis Pharmaceuticals	49,500
Bristol-Myers Squibb	16,500
Ortho Biotech	16,500
OSI Pharmaceuticals	15,000
OSI Pharmaceuticals	-

THE ASCO FOUNDATION
FOR THE YEAR ENDED
AUGUST 31, 2004

COMPANY	Net
Sanofi-Synthelabo	16,500
Sanofi-Synthelabo	16,500
Bristol-Myers Squibb	150,000
AstraZeneca Pharmaceuticals	75,000
Aventis Pharmaceuticals	250,000
Bristol-Myers Squibb	250,000
Eli Lilly and Company	300,000
Pfizer	150,000
Bristol-Myers Squibb	175,000
Bristol-Myers Squibb	175,000
Eli Lilly and Company	350,000
Ortho Biotech	179,700
Sanofi-Synthelabo	350,000
AstraZeneca Pharmaceuticals	150,000
Eli Lilly and Company	150,000
EMD Pharmaceuticals, Inc	150,000
Eli Lilly and Company	75,000
Genentech	75,000
Ortho Biotech	75,000
Pfizer	250,000
Amgen	150,000
Bristol-Myers Squibb	250,000
Prostate Cancer Foundation	50,000
Aventis Pharmaceuticals	125,000
Bristol-Myers Squibb	75,000
Genentech	250,000
Ortho Biotech	250,000
Sanofi-Synthelabo	250,000
Aventis Pharmaceuticals	75,000
AstraZeneca Pharmaceuticals	35,000
Aventis Pharmaceuticals	140,000
Bristol-Myers Squibb	35,000
EMD Pharmaceuticals, Inc	35,000
GlaxoSmithKline	35,000
Ortho Biotech	35,000
OSI Pharmaceuticals	35,000
OSI Pharmaceuticals	-
Amgen	35,000
American Pharmaceutical Partners	-
American Pharmaceutical Partners	-
Protein Design Labs, Inc	35,000
American Pharmaceutical Partners	35,000
American Pharmaceutical Partners	35,000
Sarcoma Foundation of America	35,000
Genentech	35,000
Eli Lilly and Company	35,000
Pancreatic Cancer Action Network	35,000
Arque, Inc	35,000
The American Society of Clinical Oncology	35,000
The ASCO Foundation	-
Genta	70,000
Merck KGaA	35,000
Millennium Pharmaceuticals	35,000
The Breast Cancer Research Foundation	70,000
Berlex Laboratories	35,000
Onyx Pharmaceuticals	35,000
Pancreatic Cancer Action Network	35,000
Roche Pharmaceuticals	140,000
Centocor	35,000
The Don Shula Foundation	35,000
Amgen	17,500
	\$18,017,900.00

FORM 990	SPECIAL EVENTS AND ACTIVITIES				STATEMENT	1
DESCRIPTION OF EVENT	GROSS RECEIPTS	CONTRIBUT. INCLUDED	GROSS REVENUE	DIRECT EXPENSES	NET INCOME	
BENEFIT CONCERT	323,353.	249,553.	73,800.	655,280.	<581,480.>	
TO FM 990, PART I, LINE 9	323,353.	249,553.	73,800.	655,280.	<581,480.>	

FORM 990	OTHER CHANGES IN NET ASSETS OR FUND BALANCES		STATEMENT	2
DESCRIPTION				AMOUNT
TRANSFER OF NET ASSETS				897,719.
TOTAL TO FORM 990, PART I, LINE 20				897,719.

FORM 990	OTHER EXPENSES				STATEMENT	3
DESCRIPTION	(A) TOTAL	(B) PROGRAM SERVICES	(C) MANAGEMENT AND GENERAL	(D) FUNDRAISING		
MANAGEMENT FEES TO ASCO	586,438.		586,438.			
MISCELLANEOUS OFFICE EXPENSE	85,009.		45,213.	39,796.		
BANK & CREDIT CARD FEES	2,253.	2,253.				
CONTRIBUTIONS	8,000.	8,000.				
TOTAL TO FM 990, LN 43	681,700.	10,253.	631,651.	39,796.		

FORM 990	CASH GRANTS AND ALLOCATIONS			STATEMENT	4
CLASSIFICATION	DONEE'S NAME	DONEE'S ADDRESS	DONEE'S RELATIONSHIP	AMOUNT	
PROGRAM SUPPORT	AMERICAN SOC OF CLINICAL ONCOLOGY		AFFILIATE	12385746.	
SEE STATEMENT 4A			NONE	4592500.	

2004 Merit Award Recipients

This person receives a \$2000 Merit Award check.

Rashmi Chugh, MD
University of Michigan
6290 Maplehurst Dr
Ypsilanti, MI 48197

The following 97 recipients receive a \$1500 Merit Award check.

Nabil Ahmed-El Borollosy, MD
Texas Children's Hospital
6621 FANNIN
CC.1510.00
HOUSTON, TX 77030

Mylene Bassal, MD, FRCP
University of Colorado
8155 Fairmount Drive #1427
Denver, CO 80230

Mei-Lin W Ah-See, MD
Mount Vernon Hospital
Rickmansworth Road
Northwood, Middlesex, HA6 2RN
United Kingdom

Kathryn P Beal, MD
Memorial Sloan-Kettering Cancer Center
1275 York Ave
New York, NY 10021

Naser Alzein, MD
Mayo Clinic
200 1st Sw
mayo E9
Rochester, MN 55905

Kathleen W Beekman, MD
Memorial Sloan-Kettering Cancer Center
1233 York Ave Apt 21I
New York, NY 10021

Ute Katharina Bartels, MD
The Hospital for Sick Children
555 University Ave
Toronto, ON M5G 1X8
Canada

Deepa Bhojwani, MD
New York University
Hassenfeld Childrens Center, 8th floor
317 East 34th Street
New York, NY 10016

Ethan M Basch, MD
Memorial Sloan-Kettering Cancer Center
401 East 89th Street
Apt 2B
New York, NY 10128

Fernando J Bianco, MD
Memorial Sloan-Kettering Cancer Center
475 Main Street Roosevelt Island, Apt 3-R
New York, NY 10044

2004 Merit Award Recipients

Douglas Brandoff, MD
Brown University
144 Elmgrove Avenue
Providence, RI 02906-4231

Janet E Brown, MBBS
University of Sheffield
Cancer Research Centre
weston Park Hospital
Sheffield, S10 2SJ
United Kingdom

Jeffrey A Bubis, DO
Dartmouth-Hitchcock Medical Center
1 Medical Center Drive
Lebanon, NH 03756

Neslihan Cabioglu, MD, PhD
6540 Bellows Lane, Apt. 516
Houston Texas 77030 USA

Baochong B Chang, MD, PhD
University of Texas, M.D. Anderson Cancer
Center
8222 Golf Green Circle
Houston, TX 77036

Eric Y Chen, MD, PhD
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N
MS D3-190
Seattle, WA 98109

Prakash Chinnaiyan, MD
University of Wisconsin
K4/342 Clinical Science Center
600 Highland Ave.
Madison, WI 53792

Lucian Chirieac, MD
University of Texas, M.D. Anderson Cancer
Center
Department of Pathology, Unit 085
1515 Holcombe Blvd.
Houston, TX 77030

Steve Y Cho, MD
National Cancer Institute
36 Convent Drive, MSC 4089
Building 36, Room 3B05
Bethesda, MD 20892

Kathryn Chrystal, MD
Guys Hospital
3rd Fl Thomas Guy House
St Thomas St
London, SE1 9RT
United Kingdom

Zohar A Dotan, MD
1233 York Ave Apt 17N
New York, NY 10021

Frederick C Eilber, MD
Memorial Sloan-Kettering Cancer Center
1233 York Avenue
APT 21J
New York, NY 10021

Gregory Friberg, MD
University of Chicago
1850 N Clark St Apt 3009
Chicago, IL 60614-5324

Anu G Gaba, MD
Albert Einstein Cancer Center
3411 Wayne Ave Apt 6L
Bronx, NY 10467

Gerhard Gebauer, MD
Hannover Medical School
Podbielskistrasse 380
Hannover, D 30659
Germany

2004 Merit Award Recipients

Irene M Ghobrial, MD
Mayo Clinic
200 First st, SW
Rochester, MN 55905

Stacy W Gray, MD
University of Chicago
5841 S Maryland Ave MC 2115
Chicago, IL 60637

Seza A Gulec, MD
John Wayne Cancer Institute
2200 Santa Monica Boulevard
Santa Monica, CA 90404

Sarada Gurubhagavatula, MD
Massachusetts General Hospital
33 Pond Avenue, Apt 1201
Brookline, MA 02445

Yasser Haba, MBChB, MRCP
Addenbrooke's Hospital NHS Trust
Box 193, Hills Road
Cambridge, CB1 1JR
United Kingdom

Paul Haluska, MD, PhD
Mayo Clinic
200 First St SW
Rochester, MN 55905

Andrew P Hampshire, MD
Scripps Clinic
10666 N Torrey Pines Rd
La Jolla, CA 92037

David S Hong, MD
University of Texas, M.D. Anderson Cancer
Center
1625 Tuam St
Houston, TX 77004

Katsuyuki Hotta, MD
Okayama University
2-5-1 Shikatacho
Okayama, 700-8558
Japan

Wolfgang Janni, MD
Ludwig-Maximilians-University of Munich
Am Haferfeld 11
Augsburg, 86156
Germany

Kevin Victor Jasas, FRACP
National Cancer Institute of Canada
736 Bay St Apt 3103
Toronto, ON M5G 2M4
Canada

Antonio Jimeno, MD, PhD
Hospital Universitario
The SKCCC at Johns Hopkins
1650 Orleans St Rm 162A
Baltimore, MD 21231-1000

Gnanamba Varuni Kondagunta, MD
Memorial Sloan-Kettering Cancer Center
303 E 60th St Apt 22-I
New York, NY 10022

Henderikus Kramer, MD
Groningen University Hospital
Snelliusstraat 138
Groningen, 9727 JS
Netherlands

Rebecca S Kristeleit, MD
Institute of Cancer Research/Royal Marsden
Hospital
15 Cotswold Rd
Sutton, SM2 5NG
United Kingdom

2004 Merit Award Recipients

Monika K Krzyzanowska, MD, MPH
Dana-Farber Cancer Institute
44 Binney Street
454-BRK, Suite 21-23
Boston, MA 02115

Allison W Kurian, MD
Stanford University
Oncology Day Care Center
Room H-0274
Stanford, CA 94305-5216

Christopher S Lathan, MD
Dana-Farber Cancer Institute
2 Vogel St
W Roxbury, MA 02132

Brian D Lawenda, MD
130 Bowdoin St #1501
Boston, MA 02108

Jonathan H Lee, MD
John Wayne Cancer Institute
2200 Santa Monica Blvd.
Santa Monica, CA 900525

Chooi Lee, MBBS
Institute of Cancer Research/Royal Marsden
Hospital
15, Cotswold Road
Sutton, SM2 5NG
United Kingdom

Gregory D Leonard, MD
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021

Douglas A Levine, MD
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
Box 225
New York, NY 10021

Nina S Liu, MD
University of Texas, M.D. Anderson Cancer
Center
1515 Holcombe Blvd Box 10
Houston, TX 77030

Sherene Loi, MD
c/o Breast International Group
7th Floor
121 Boulevard de Waterloo
Brussels 1000
Belgium

Jennifer W Mack, MD
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115

Nicholas R Maisey, MD
Institute of Cancer Research/Royal Marsden
Hospital
Royal Marsden Hospital
Fulham Road
London, SW3 6JJ
United Kingdom

Christine Mayr, MD
Ludwig-Maximilians-University of Munich
Adlzreiterstr.9
München, 80337
Germany

Monika L Metzger, MD
St. Jude Children's Research Hospital
332 N Lauderdale St.
Memphis, TN 38105-2794

Madhu V Midathada, MD
University of Arkansas
4301 W Markham St
Little Rock, AR 72205

2004 Merit Award Recipients

Julian R Molina, MD, PhD
Mayo Clinic
4458 Savannah Dr NW
Rochester, MN 55901

Daniel Morgensztern, MD
University of Miami
20355 NE 34th Ct Apt 1622
Miami, FL 33180

Melinda M Mortenson, MD
University of California, Davis
4501 X Street, Suite 3010
UC Davis Cancer Center
Sacramento, CA 95817

Sethupathi R Muthuramalingam, MRCP
Cancer Research UK
17, Victoria court, 5, London Road
Headington
Oxford, OX 3 7SP
United Kingdom

Rita Nanda, MD
University of Chicago
5841 S. Maryland Ave.
MC 2115
Chicago, IL 60637-1470

Chongxian Pan, MD, PhD
Indiana University
535 Barnhill Dr Rm 473
Indianapolis, IN 46202

David J Park, MD
University of Southern California, Norris
1441 Eastlake Ave
Los Angeles, CA 90033

Hitendra Patel, MD
University of Pittsburgh
5150 Center Ave, 5th Fl
Pittsburgh, PA 15232

Bilal Piperdi, MD
Albert Einstein Cancer Center
3411 Wayne Ave Apt 3L
Bronx, NY 10467

Joseph F Pizzolato, MD
Memorial Sloan-Kettering Cancer Center
504 E 63rd St Apt 25L
New York, NY 10021

Sanjay Popat, PhD, MRCP
Institute of Cancer Research/Royal Marsden
Hospital
Cotswold Road
Sutton, SM2 5NG
United Kingdom

Victoria Price, MD
Hospital for Sick Children
555 University avenue
Toronto, ON M5G1X8
Canada

Brigitte K Rack, MD
Munich University
Kleiststrasse 18
Dachau, 85221
Germany

Ravi D Rao, MD
Mayo Clinic
1340 Arthur Ln NW
Rochester, MN 55901

Jason A Salganick, MD
University of Texas, M.D. Anderson Cancer
Center
1515 Holcombe Blvd Box 87
Houston, TX 77030-4095

Rohini Sharma, MBBS
Sydney Cancer Center
208/187 liverpool street
sydney, nsw/2000
Australia

2004 Merit Award Recipients

Simron Singh, MD
Princess Margaret Hospital
555 Yonge St Apt 803
Toronto, ON M4Y 3A6
Canada

Joo Hyuk Sohn, MD
Yonsei University
Yonsei Cancer Ctr
Seodaemun-Gu Shznchon-Dong 134
Seoul, 120-752
Republic of Korea

Wenru Song, MD, PhD
Stanford University
905 Clark Way
Palo Alto, CA 94304

Helen Steed, MD
University of Toronto
610 University Ave
Room M-700
Toronto, ON M5G 2M9
Canada

Dejka M Steinert, MD
University of Texas, M.D. Anderson Cancer
Center
7300 Brompton St Apt #5532
Houston, TX 77025

Andrew J Stephenson, MBBS
Memorial Sloan-Kettering Cancer Center
504 East 63rd Street, Apt 23L
New York, NY 10021

John J Strouse, MD
Johns Hopkins University
600 N Wolfe Street
800 CMSC
Baltimore, MD 21287
Rebecca Suk, MD
Massachusetts General Hospital
9 Hancock St Apt 2
Boston, MA 02114

Mark L Sundermeyer, MD
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

Wade T Swenson, MD
The University of Iowa
C 316 GH
200 Hawkins Drive
Iowa City, IA 52242

Kazumasa Takenaka, MD
Kyoto University
Kamitakano Hatagada Cho 25 101
Sakyo Ku
Kyoto, 606 0082
Japan

Kullathorn Thephamongkhol, MD
McMaster University
(c/o Rose Vanbeek or Ann Fucic)
699 Concession Street
Hamilton, ON L8V 5C2
Canada

Anna Tinker, MD
British Columbia Cancer Agency
1310 W 10th Ave Apt 208
Vancouver, BC V6H 1J6
Canada

Carol A Townsley, MD
Princess Margaret Hospital
22 Roosevelt Road
Toronto, ON M4J 4T6
Canada

James Y Tsai, MD
The Brown University
15 Cedar Pond Drive, Apt 12
Warwick, RI 02886

2004 Merit Award Recipients

Anne S Tsao, MD
University of Texas, M.D. Anderson Cancer
Center
MD Anderson Cancer Center
1515 Holcombe Blvd Bx 432
Houston, TX 77030

Jennifer F Tseng, MD
University of Texas, M.D. Anderson Cancer
Center
1515 Holcombe Blvd
Box 444
Houston, TX 77030

Samir D Undevia, MD
University of Chicago
5841 South Maryland Avenue
MC 2115
Chicago, IL 60637

Mirjana Urosevic, MD
University Hospital Zurich
Gloriastrasse 31
Zurich, CH-8091
Switzerland

Annette Vielhaber, MD
Beth Israel Medical Center
First Avenue at 16th Street
New York, NY 10003

Hirokazu Watanabe, MD
Kobe University
7-5-2, Kusunoki-cho, Chu-ku
650-0017
Kobe, JAPAN

Kyle D Weaver, MD
Johns Hopkins University
814 Hunterian
724 N. Wolfe St.
Baltimore, MD 21212

Eric S Winer, MD
Tufts-New England Medical Center
750 Washington St
Box 245
Boston, MA 02111

Yuning Wong, MD
Fox Chase Cancer Center
333 Cottman Avenue
Fox Chase Cancer Center, Department of
Med Oncology
Philadelphia, PA 19111

Pia Wulfing, MD
University of Munster
Antoniusstr 15
Munster, 48151
Germany

National Institute of Health
c/o Sen H Zhuang MD,PHD
National Cancer Institute
329 Prettyman Drive, Unit D
Rockville, MD 20850

GI Merit Awards

Ian Chau

Royal Marsden Hospital

\$2,000

Suzannah Mawdsley, MD

The Gray Cancer Institute

\$2,000

Oliver Stoeltzing, M.D.

University of Regensburg

\$2,000

Wells A Messersmith, MD

Johns Hopkins

\$1,500

Barbara Jung, MD

University of California, San Diego

\$1,500

Olivier Glehen, MD

Centre Hospitalier Lyon-Sud

\$2,000

Elizabeth Nicole Omer

Huntsman Cancer Institute

\$1,500

Gunnar Folprecht, MD

University Hospital "Carl Gustav Carus"

\$2,000

Jennifer F Tseng, MD

UT MD Anderson Cancer Center

\$1,500

Adam C Berger, MD

Fox Chase Cancer Center

\$1,500

Cheryl Ho, MD

BC Cancer Agency

\$2,000

Carol Townsley, MD

Princess Margaret Hospital

\$2,000

Wu Zhang, M.D

USC/Norris Comprehensive Cancer Center

\$1,500

Tomonori Yano

National Cancer Center Hospital East

\$2,000

Todd W Bauer, M.D.

UT-MDACC

\$1,500

Michael Hall, MD

University of Chicago

\$1,500

Michael Gibson, MD

STATEMENT 4A

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
\$1,500

Maria L Amador, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
\$1,500

Kathryn F Chrystal, FRACP

Guy's Hospital

\$2,000

Genoveva Murillo

University of Illinois at Chicago

\$1,500

Torsten Liersch, MD

University of Goettingen

\$2,000

Sanjay Papat, MBBS, MRCP, PhD

Institute of Cancer Research

\$2,000

Kerry A Cheong, BMBS

Guys Hospital

\$2,000

Dana Rathkopf, MD

MSKCC

\$1,500

Stephen Winikoff, M.D.

University of Pittsburgh

\$1,500

2004 ASCO FOUNDATION GRANTS PROGRAM RECIPIENTS

ADVANCED CLINICAL RESEARCH AWARD RECIPIENT - \$450,000

Vered Stearns, MD

Johns Hopkins University

“Clinical Investigation of the Histone Deacetylase Inhibitor SAHA, Single Agent or in Combination, in Women with Newly Diagnosed Breast Cancer”

CAREER DEVELOPMENT AWARD RECIPIENTS - \$170,100/PER RECIPIENT

Sylvia Adams, MD

New York University School of Medicine

“Phase I/II Evaluation of Imiquimod as Vaccine Adjuvant in Malignant Melanoma”

Shabbir M.H. Alibhai, MD

University of Toronto

“A Prospective, Longitudinal Study to Examine Health Effects of Androgen Deprivation Therapy on Older Men with Prostate Cancer”

Nancy N. Baxter, MD, PhD

University of Minnesota

“Patterns of Cancer Care in the Disabled”

Jacqueline Nieto Casillas, MD

University of California at Los Angeles

“Transitioning Adolescent and Young Adult Childhood Cancer Survivors to Adult Health Care”

Sophie Dessureault, MD, PhD

H. Lee Moffitt Cancer Center

“A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines in Patients with Melanoma”

Kavita M. Dhodapkar, MD

Rockefeller University

“Interaction of Innate and Adaptive Immunity to Glioma”

Missak Haigentz, MD

Albert Einstein College of Medicine

“Clinical and Translational Studies of Depsipeptide, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patient With Squamous Cell Carcinoma of the Head and Neck”

John Heymach, MD, PhD

Dana-Farber Cancer Institute

“VEGF Inhibitors for Non-Small Cell Lung Cancer: Markers of Activity and Resistance”

Jennifer Ligibel, MD

Dana-Farber Cancer Institute

“Pilot Study of the Effects of an Exercise Intervention on Insulin Levels in Breast Cancer Survivors”

William H. Matsui, MD

Johns Hopkins University

“Multiple Myeloma Stem Cells as Therapeutic Targets”

Yael P. Mosse, MD

Children's Hospital of Philadelphia

“High-Throughput Genomics to Identify a Hereditary Neuroblastoma Predisposition Gene”

Michael B. Sawyer, MD

Cross Cancer Institute

“Pharmacogenetics of Paclitaxel Metabolism in Ovarian Cancer Patients”

Melanie B. Thomas, MD

University of Texas, MD Anderson Cancer Center

“Targeted Therapies for Biliary Cancer”

Martin R. Weiser, MD

Memorial Sloan-Kettering Cancer Center

“The MET Oncogene and Human Colorectal Cancer Progression and Metastases”

Margaret K. Yu, MD

University of Utah

“Global DNA Methylation, a Potential Predictor of Aggressive Chronic Lymphocytic Leukemia, and Cladribine as a Potential DNA Methylation Inhibitor”

YOUNG INVESTIGATOR AWARD RECIPIENTS - \$35,000/PER RECIPIENT

Joshi J. Alumkal, MD

Johns Hopkins University

“DNA Methylation as a Predictor of Biochemical Recurrence After Radical Prostatectomy”

Mary Y. Armanios, MD

Johns Hopkins University

“Telomerase and Telomere Length in Tumorigenic and Non-Tumorigenic Breast Cancer Cells”

Murali Beeram, MD, MBBS

University of Texas Health Science Center at San Antonio

“Therapeutic Modulation of Anti-Estrogenic Resistance Through Histone Deacetylase Inhibition in Breast Cancer- a New Paradigm”

Hossein Borghaei, DO

Fox Chase Cancer Center

“Production and Characterization of Monoclonal Antibodies Against Tumor Endothelial Marker (TEM7R)”

Ron Bose, MD, PhD

Johns Hopkins University

“Identification of Substrates of the Her2/neu Tyrosine Kinase in Breast Cancer Cell Lines Using Chemical Rescue of a Her2/neu Catalytic Loop Point Mutation”

Januario E. Castro, MD

University of California, San Diego

“Induction of Apoptosis and Immunomodulation on CLL B Cells Using DNA-Oligodeoxynucleotides”

Mwe Mwe Chao, MD

University of Michigan

“Mechanisms of MLL-CALM-Mediated Leukemic Transformation”

Eric Y. Chen, MD, PhD

Fred Hutchinson Cancer Research Center

“Adoptive Anti-CD20 T-Cell Immunotherapy for Follicular Non-Hodgkin's Lymphoma”

Adam D. Cohen, MD

Memorial Sloan-Kettering Cancer Center

“Strategies to Enhance CD8 T Cell Memory Following DNA Immunization Against Melanoma”

Anderson B. Collier, MD

University of Texas Southwestern Medical Center

“The Frequency, Inheritance, and Prognostic Significance of Polymorphisms in the RASSF1A Gene in Children with Wilms Tumors”

Maricer P. Escalon, MD

University of Texas, MD Anderson Cancer Center

“Development of Novel Immunotherapeutic Strategies for Epstein-Barr Virus (EBV)-Associated Malignancies”

Jorge A. Garcia, MD

University of California, San Francisco

“Enhancement of Prostate Tissue Specific Immune Response After Cytokine Administration”

Rani George, MD, PhD

Dana-Farber Cancer Institute

“Cloning and Characterization of a Sympathetic Nervous System Mutant, CC2, in the Zebrafish”

Irene M. Ghobrial, MD

Mayo Clinic

“Characterization of the Anti-Apoptotic Pathways in Post Transplant Lymphoproliferative Disorders (PTLD)”

Karyn Aalami Goodman, MD

Stanford University

“Long-Term Outcomes of Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin's Disease”

Neil Dwayne Gross, MD

Memorial Sloan-Kettering Cancer Center

“Urinary PGE-M as a Biomarker in Head and Neck Squamous Cell Carcinoma (HNSCC)”

Supriya K. Gupta, MD

University of Chicago Hospitals

“Geriatric Assessment of Older Prostate Cancer Patients at Risk for Functional and/or Cognitive Decline”

David Sanghyun Hong, MD

University of Texas, MD Anderson Cancer Center

“SRC Kinase Inhibition with BMS-354825 in Pancreatic Cancer Models”

Naomi Noelle Hildegard Hunder, MD

Fred Hutchinson Cancer Research Center

“Evaluation of Mesothelin as a Target for Immunotherapy of Ovarian Cancer”

Hanna Yoko Irie, MD, PhD

Dana-Farber Cancer Institute

“Investigating the Role of IGF Signaling in Mammary Cell Survival and Tumorigenesis Using a 3-D Epithelial Acini Model”

David Guy Kirsch, MD, PhD

Massachusetts General Hospital

“Determining Whether Apoptosis is Important to Cure Lung Adenocarcinomas with Radiation Therapy.”

Fengming Kong, MD, PhD

University of Michigan

“A Pilot Study to Evaluate the Impact of Functional Imaging on Predicting Local Tumor Control and Lung Toxicity in the Treatment of Non-Small Cell Lung Cancer”

Sheeba Koshy, MD

University of Texas, MD Anderson Cancer Center

“Targeting Grb2 in the Treatment of Imatinib Mesylate Resistant Chronic Myelogenous Leukemia”

Alice Lee, MD

Columbia University

“Role of Id2 in Neuroblastoma Angiogenesis”

Qi Liu, MD, PhD

University of Texas, MD Anderson Cancer Center

“Novel Strategy to Validate Surrogate Markers of Antiangiogenic Therapy in Renal Cell Carcinoma”

Ellie G. Maghami, MD

Memorial Sloan-Kettering Cancer Center

“RNAi-Based Gene Therapy in Head and Neck Cancer: Application to SCCRO, an Oncogene Amplified in Mucosal Squamous Cell Carcinomas”

Wells A. Messersmith, MD

Johns Hopkins University

“Pharmacogenetic Study of Gefitinib (Iressa)”

Daniel T. Milton, MD

Memorial Sloan-Kettering Cancer Center

“A Phase I/II Study of Fixed Doses of Daily Gefitinib with Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer”

Vu H Nguyen, MD

University of California, San Francisco

“In Vivo Properties of Ex Vivo Expanded CD25+ T Cells”

Kepal N. Patel, MD

Memorial Sloan-Kettering Cancer Center

“Therapeutic Targeting of MUC1 in Aggressive Thyroid Cancer”

William J. Petty, MD
Dartmouth Hitchcock Medical Center
“Mechanisms for an Active Targeted Combination Therapy”

Christine A. Pratilas, MD
Memorial Sloan-Kettering Cancer Center
“Development of Novel Therapeutic Strategies for Cancers with Mutational Activation of the MAP Kinase Pathway”

Tatiana M. Prowell, MD
Johns Hopkins University
“Surrogate Markers of Response: A Phase II Pilot Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy”

Karen L. Riedl, MD
University of California, Los Angeles
“A Phase I Trial of Intratumoral Administration of Autologous Dendritic Cells and Celecoxib in Advanced Non-Small Cell Lung Cancer”

Manuel F. Rosado, MD
University of Miami
“Distinct IL-4 Signaling in Germinal Center B Cell-like and Activated B Cell-like Diffuse Large B-Cell Lymphoma-Potential Therapeutic Applications”

Jacalyn M. Rosenblatt, MD
Beth Israel Deaconess Medical Center
“Dendritic Cell (DC) Fusion Vaccines as Immunotherapy in Acute Myeloid Leukemia”

Mika Sovak, MD
Memorial Sloan-Kettering Cancer Center
“Evaluation of the Novel Cytotoxic Agent LY573636”

Janette L. Vardy, MD
Princess Margaret Hospital
“Cognitive Function and Fatigue in Cancer Patients After Chemotherapy; a Longitudinal Controlled Study in Patients with Colorectal Cancer”

Martha Wadleigh, MD
Dana-Farber Cancer Institute
“Establishing National Cohort Studies in Hematologic Diseases”

Elisha Waldman, MD
Memorial Sloan-Kettering Cancer Center
“T Cell Homing in Intestinal Graft-Versus-Host-Disease”

Elias T. Zambidis, MD, PhD

Johns Hopkins University

“Study of the Origins of Primitive Hematopoietic Progenitors Derived from Human Pluripotent Stem Cells”

TOTAL INCLUDED ON FORM 990, PART II, LINE 22

16978246.

FORM 990 OTHER REVENUE NOT INCLUDED ON FORM 990 STATEMENT 5

DESCRIPTION	AMOUNT
RELATED ENTITY REVENUE REPORTED ON A SEPARATE BASIS	42,205,673.
TOTAL TO FORM 990, PART IV-A	42,205,673.

FORM 990 OTHER EXPENSES NOT INCLUDED ON FORM 990 STATEMENT 6

DESCRIPTION	AMOUNT
BENEFIT CONCERT EXPENSE	655,280.
RELATED ENTITY EXPENSE REPORTED ON A SEPARATE BASIS	37,288,704.
TOTAL TO FORM 990, PART IV-B	37,943,984.

FORM 990 OTHER REVENUE INCLUDED ON FORM 990 STATEMENT 7

DESCRIPTION	AMOUNT
BENEFIT CONCERT EXPENSE	<655,280.>
TOTAL TO FORM 990, PART IV-A	<655,280.>

Primary Exempt Purpose STATEMENT 10

Through its grants program, The ASCO Foundation supports specialized educational programs of the highest quality in cancer care and prevention for individuals who provide health care in the field of oncology, and the dissemination of information about cancer and cancer treatment to patients and their families. Through its grants program, the Foundation also supports, encourages and recognizes excellence in clinical research in the field of oncology.

For so long as ASCO exists, all net funds raised by The ASCO Foundation above those necessary to pay for its operating expenses are irrevocably committed to the funding of oncology research that is determined by ASCO to be meritorious and to the funding of physician and patient education programs administered by ASCO.

Four Largest Programs STATEMENT 11

- 1. The ASCO Foundation Grants Program** - This program is among the largest of any medical professional society. Hundreds of innovative research initiatives have received support through this program. This program is critical to ASCO's continued effort to ensure timely information and quality cancer care for present and future generations. In addition to providing financial support for research, the ASCO awards encourage young investigators to pursue a career of clinical oncology research. Generous support from industry and foundations has enabled ASCO to award an increased number of grants each year. **\$4,718,050**
- 2. 2004 ASCO Annual Meeting** - This meeting is considered the premier educational and scientific event in the oncology community. ASCO's 2004 Annual Meeting in New Orleans attracted more than 28,000 attendees from all over the world. **\$5,175,450**
- 3. 2004 ASCO Gastrointestinal Cancers Symposium** – This meeting offers educational sessions and abstract presentations focused on a different disease site each day: Day 1 focused on upper gastrointestinal (esophageal and gastric) cancers; Day 2 addressed pancreatic and hepatobiliary cancers; and Day 3 focused on colon and rectal cancers. **\$1,192,500**
- 4. People Living With Cancer.org** - This award-winning website provides oncologist-vetted cancer information for both the patient and his/her oncologist with the latest guidelines and knowledge available for 50 types of cancer and their treatments, clinical trials, coping, and side effects. The site also includes an oncologist database, live chat series, message boards, a drug database, and links to patient support organizations. The site is designed to help people with cancer make informed health-care decisions. **\$1,106,730**
- 5. Other Program Contributions to ASCO-** **\$4,795,769**
- Total Program Expense to Form 990 Part III, Line f** **\$16,988,499**

THE ASCO FOUNDATION BOARD OF DIRECTORS
Roster of Current Members
2003-2004

2/25/04

CHAIR

Larry Norton, MD
Memorial Sloan-Kettering Cancer Center
205 East 64th Street, Concourse Level
New York, NY 10021
Phone: (212) 639-5319
Fax: (212) 303-9120
Email: nortonl@mskcc.org
Specialty: Med Onc
Chair Term: 2002-2003
Cmte Term: 2002-2005
Assistant: Stephanie Orlando
Asst. Phone: (212) 639-5319
Asst. Email: orlandos@mskcc.org

SECRETARY

Douglas W. Blayney, MD
University of Michigan
C365 MedInn, Box 0848
1500 E. Medical Center Drive
Ann Arbor, MI 48109-0848
Phone: (734) 615-7167
Fax: (734) 615-2109
Email: dblayne@med.umich.edu
Specialty: Med Onc/Hem
Cmte Term: 2001-2004
Assistant: Krystal Lichlyter
Asst. Phone: (734) 615-7228
Asst. Email: kjlich@umich.edu

TREASURER

Ronald E. Beller, PhD
ASCO
1900 Duke Street, Suite 200
Alexandria, VA 22314
Phone: (703) 299-0150
Fax: (703) 684-6062
Email: bellerr@asco.org
Cmte Term: 2002-2003
Assistant: Jackie Kirch
Asst. Phone: (703) 299-1198
Asst. Email: kirchj@asco.org

CHIEF EXECUTIVE OFFICER

Charles M. Balch, MD
ASCO
1900 Duke Street, Suite 200
Alexandria, VA 22314
Phone: (703) 299-1080
Fax: (703) 684-6062
Email: balchc@asco.org
Assistant: Roseanna Thoman
Asst. Phone: (703) 299-1081
Asst. Email: thomanr@asco.org

5TH MEMBER AT LARGE

Michael B. Troner, MD
Oncology Hematology Group of South Florida
8940 N Kendall Drive, Suite 300 East
Miami, FL 33176-2132
Phone: (305) 595-2141 (Ext. 1772)
Fax: (305) 675-0966 Cell: (305) 318-2228
After 5 pm: (305) 595-1134
Email: mtroner@bellsouth.net
Specialty: Med Onc
Cmte Term: 2001-2004
Assistant: Julio Castillo
Asst. Email: N/A

EDITOR, NEWS & VIEWS

Sarah S. Donaldson, MD
Stanford University Medical Center
Department of Radiation Oncology
875 Blake Wilbur Drive, Rm G225
Stanford, CA 94305-5847
Phone: (650) 725-4020
Fax: (650) 725-3865
Email: sarah@reyes.stanford.edu
Specialty: Rad Onc
Cmte Term: 2002-2005
Assistant: Andrea White
Asst. Email: andrea@reyes.stanford.edu

THE ASCO FOUNDATION BOARD OF DIRECTORS
Roster of Current Members
2003-2004

2/25/04

Martin D. Abeloff, MD
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Weinberg Building
401 N Broadway, Suite 1100
Baltimore, MD 21231
Phone: (410) 955-8822
Fax: (410) 955-6787
Email: abeloma@jhmi.edu
Specialty: Med Onc
Cmte Term: 2001-2004
Assistant: Michele Pass
Asst. Email: mpass@jhmi.edu

Joseph S. Bailes, MD
P.O. Box 131599
The Woodlands, TX 77393-1599
Cell: (214)725-6100
Fax: (936) 273-9385
Home : 32 Waterford Lake
The Woodlands, TX 77381
Email: bailesj@houston.rr.com
Specialty: Med Onc
Cmte Term: 2001-2004

George J. Bosl, MD
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021-0005
Phone: (212) 639-8473
Fax: (212) 717-3550
Email: boslg@mskcc.org
Specialty: Med Onc
Cmte Term: 2003-2006
Assistant: Theresa Neri
Phone: (212) 639-5851
Asst. Email: nerit@mskcc.org

Paul A. Bunn, Jr, MD
University of Colorado Cancer Center
4200 East 9th Avenue
Denver, CO 80220-3706
Phone: (303) 315-3007
Fax: (303) 315-3304
Email: paul.bunn@uchsc.edu
Specialty: Med Onc
Cmte Term: 2003-2006
Assistant: Pia Hirsch
Asst. Email: pia.hirsch@uchsc.edu

George P. Canellos, MD
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115-6013
Phone: (617) 632-3470
Fax: (617) 632-3477
Email: george_canellos@dfci.harvard.edu
Specialty: Med Onc/Hem
Cmte Term: 2001-2004
Assistant: Ellen Brinker
Asst. Email: ellen_brinker@dfci.harvard.edu

John R. Durant, MD
2030 Country Ridge Place
Birmingham, AL 35243-4320
Phone: (205) 969-2188
Fax: (205) 969-2180
Email: msdurant@aol.com
Cmte Term: 2003-2006

Lawrence H. Einhorn, MD
Indiana Cancer Pavilion
Indiana University
535 Barnhill Drive, Room 473
Indianapolis, IN 46202-5112
Phone: (317) 274-0920
Fax: (317) 274-3646
Email: leinhorn@iupui.edu
Specialty: Med Onc
Cmte Term: 2003-2006
Assistant: Jan Elrod & Cathy Lowe
Asst. Email: jelrod@iupui.edu
& calowe@iupui.edu

THE ASCO FOUNDATION BOARD OF DIRECTORS

2/25/04

Roster of Current Members

2003-2004

Nora Anita Janjan, MD

M.D. Anderson Cancer Center
University of Texas
1515 Holcombe Boulevard, Suite 97
Houston, TX 77030-4009
Phone: (713) 563-2326
Fax: (713) 563-2326
Email: njanjan@mdanderson.org
Specialty: Rad Onc
Cmte Term: 2003-2006
Assistant: Ella Forel
Phone: (713) 563-2375
Asst. Email: eforel@mdanderson.org

LaSalle D. Leffall, MD

Howard University Hospital
2041 Georgia Avenue, NW
Washington, DC 20060-0001
Phone: (202) 865-6237
Fax: (202) 865-3130
Email: lleffall@fac.howard.edu
Cmte Term: 2003-2006
Assistant: Michele Berry

Allen S. Lichter, MD

University of Michigan Medical School
Office of the Dean
Medical Science Building 1, Room 4101
1301 Catherine Street
Ann Arbor, MI 48109-0624
Phone: (734) 764-8175
Fax: (734) 763-4936
Email: alichter@umich.edu
Specialty: Rad Onc
Cmte Term: 2003-2006
Assistant: Carol Jarema
Asst. Email: cjarema@med.umich.edu

Robert J. Mayer, MD

Dana-Farber Cancer Institute
44 Binny Street, Room 1608
Boston, MA 02115-6084
Phone: (617) 632-3474
Fax: (617) 632-2260
Email: robert_mayer@dfci.harvard.edu
Specialty: Med Onc/Hem
Cmte Term: 2002-2005
Assistant: Kim Bremner
Asst. Email: kim_bremner@dfci.harvard.edu

Ellen V. Sigal, PhD

Friends of Cancer Resrch
3299 K Street, NW, Suite 100
Washington, DC 20007
Phone: (202) 944-6710
Fax: (202) 333-7840
Email: esigal@sigal.com
Cmte Term: 2002-2005
Assistant: Marie Donohue
Asst. Phone: (202) 944-6711
Asst. Email: mtonohue@focr.org

Joseph V. Simone, MD

Simone Consulting
4999 Oak Trail Drive
Dunwoody, GA 30338
Phone: (770) 392-0896
Email: joseph.simone@simoneconsulting.com
Specialty: Ped Onc/Hem
Cmte Term: 2002-2005

THE ASCO FOUNDATION BOARD OF DIRECTORS
Roster of Current Members
2003-2004

2/25/04

EX OFFICIO – ASCO President

Margaret A. Tempero, MD
UCSF Comprehensive Cancer Center
1600 Divisadero Street
7th Floor B-726
San Francisco, CA 94115
Phone: (415) 353-7528
Fax: (415) 353-9636
Email: mtempo@medicine.ucsf.edu
Chair Term: 2003-2004
Cmte Term: 2002-2005
Assistant: Pamela Gonzales
Asst. Email: pamelag@medicine.ucsf.edu

LAWYER

Dina L. Michels, Esq.
Ropes & Gray LLP
One Franklin Square
1301 K Street, NW, Suite 800 East
Washington, DC 20005-7008
Phone: (202) 626-3908
Fax: (202) 626-3961
Email: Dmichels@ropesgray.com

STAFF

Julia J. McCormack
Executive Director
The ASCO Foundation
1900 Duke Street, Suite 200
Alexandria, VA 22314
Phone: (703) 519-1418
Fax: (703) 684-8645
Email: mccormaj@asco.org

Dee L. Chamberlin
Director, Corporate Development
The ASCO Foundation
1900 Duke Street, Suite 200
Alexandria, VA 22314
Phone: (703) 299-1192
Fax : (703) 684-8645
Email: chamberd@asco.org

Donna Williams
Executive Assistant
The ASCO Foundation
1900 Duke Street, Suite 200
Alexandria, VA 22314
Phone: (703) 519-1417
Fax: (703) 684-8645
Email: williamd@asco.org

Application for Extension of Time To File an Exempt Organization Return

▶ File a separate application for each return.

- If you are filing for an **Automatic 3-Month Extension**, complete only **Part I** and check this box **X**
- If you are filing for an **Additional (not automatic) 3-Month Extension**, complete only **Part II** (on page 2 of this form).

Note: Do not complete Part II unless you have already been granted an automatic 3-month extension on a previously filed Form 8868.

Part I Automatic 3-Month Extension of Time - Only submit original (no copies needed)

Note: Form 990-T corporations requesting an automatic 6-month extension - check this box and complete Part I only

All other corporations (including Form 990-C filers) must use Form 7004 to request an extension of time to file income tax returns. Partnerships, REMICs and trusts must use Form 8736 to request an extension of time to file Form 1065, 1066, or 1041.

Type or print	Name of Exempt Organization ASCO FOUNDATION	Employer identification number 31-1667995
	Number, street, and room or suite no. If a P.O. box, see instructions. 1900 DUKE STREET, NO. 200	
	City, town or post office, state, and ZIP code. For a foreign address, see instructions. ALEXANDRIA, VA 22314	

Check type of return to be filed (file a separate application for each return):

- | | | |
|--|---|------------------------------------|
| <input checked="" type="checkbox"/> Form 990 | <input type="checkbox"/> Form 990-T (corporation) | <input type="checkbox"/> Form 4720 |
| <input type="checkbox"/> Form 990-BL | <input type="checkbox"/> Form 990-T (sec. 401(a) or 408(a) trust) | <input type="checkbox"/> Form 5227 |
| <input type="checkbox"/> Form 990-EZ | <input type="checkbox"/> Form 990-T (trust other than above) | <input type="checkbox"/> Form 6069 |
| <input type="checkbox"/> Form 990-PF | <input type="checkbox"/> Form 1041-A | <input type="checkbox"/> Form 8870 |

- If the organization does **not** have an office or place of business in the United States, check this box
- If this is for a **Group Return**, enter the organization's four digit Group Exemption Number (GEN) _____. If this is for the **whole** group, check this box . If it is for part of the group, check this box and attach a list with the names and EINs of all members the extension will cover.

1 I request an automatic 3-month (6-month, for **990-T corporation**) extension of time until APRIL 15, 2005 to file the exempt organization return for the organization named above. The extension is for the organization's return for:

▶ calendar year _____ or

▶ tax year beginning SEP 1, 2003, and ending AUG 31, 2004.

2 If this tax year is for less than 12 months, check reason: Initial return Final return Change in accounting period

3a If this application is for Form 990-BL, 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions \$ _____

b If this application is for Form 990-PF or 990-T, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit \$ _____

c **Balance Due.** Subtract line 3b from line 3a. Include your payment with this form, or, if required, deposit with FTD coupon or, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions \$ _____ **N/A**

Signature and Verification

Under penalties of perjury, I declare that I have examined this form, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete, and that I am authorized to prepare this form.

Signature ▶ *Shirley L. Wood* Title ▶ *CPA* Date ▶ *11/6/05*

LHA For Paperwork Reduction Act Notice, see instruction